...Asahi Kasei Pharma ATS907 Ophthalmic disease Glaucoma Phase II Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) Y-39983...

...>=120 minutes vs. the vehicle-treated control eye (p<0.05). AMA0076 also led to lower hyperemia vs. Y-39983...

...minutes vs. the vehicle-treated control eye (p<0.05). Additionally AMA0076 led to lower ocular hyperemia vs. Y-39983...